We focus on development, standardization and validation of in vitro method of cultivation of fastidious bacterial species, namely Chlamydia pneumoniae (CPN).

These obligate intracellular bacteria grow only inside mammalian cells in cell culture. For this reason, Chlamydia cannot be grown on artificial bacteriological medium. This characteristic makes in vitro cultivation of Chlamydia very difficult.

Our further goal is to contribute to development of new effective anti-chlamydia substances. CPN is actually the main cause of pneumonia, asthma and other lower respiratory tract diseases. It is also suspect of causing the development of atherosclerotic disease, multiple sclerosis, etc. Antibiotic therapy of chlamydia infection is associated with numerous problems. Due to this fact we work on identification and testing of substances from natural sources with inhibitory effect on CPN.